• Publications
  • Influence
Mesothelin-family proteins and diagnosis of mesothelioma
Determined serum concentrations of soluble mesothelin-related proteins (SMR) in serum could be a useful marker for diagnosis of mesothelioma and to monitor disease progression and might also prove helpful for screening asbestos-exposed individuals for early evidence of mesosarcoma. Expand
Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms.
It is demonstrated that HE4 can also be detected in the urine at a specificity level of 94.4%, indicating that measuring HE4 in urine may aid diagnosis and the monitoring of response to therapy. Expand
MESOMARK: a potential test for malignant pleural mesothelioma.
The MESOMARK assay is analytically robust and may be useful for the detection and management of mesothelioma. Expand
Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.
The CM may outperform CA 125 alone in a longitudinal screening program as well as in a diagnostic setting, and has temporal stability at least as high as CA 125. Expand
SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
Assays measuring SMRP (mesothelin) and HE4 (a secreted protease) in serum and other body fluids (including urine for SMRP) are likely to be clinically useful for patients with ovarian cancer, as dataExpand
Secretion of functional antibody and Fab fragment from yeast cells.
Yeast strains that secrete functional mouse-human chimeric antibody and its Fab fragment into the culture medium are constructed and chimeric whole antibody exhibited antibody-dependent cellular cytot toxicity activity but not complement-dependent cytotoxicity activity. Expand
Soluble mesothelin-related protein--a blood test for mesothelioma.
Identification of tumor marker for mesothelioma (MM) might prove useful in diagnosis as well as for monitoring tumor in response to therapy and for screening at-risk individuals. We tested theExpand
Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation
Data from ongoing experiments show that intratumoral injection of a combination of mAbs to CD137+PD-1+CTLA4+CD19 can induce complete regression and dramatically prolong survival also in the TC1 carcinoma and B16 melanoma models, suggesting that the approach has general validity. Expand
Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma‐associated antigen p97
Conjugates (immunotoxins) comprising ricin A‐chain and monoclonal antibody 96.5, which is specific for human melanoma‐associated antigen p97, inhibited protein synthesis and colony formation ofExpand
Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors
Tumor-specific CD8+ cytotoxic T lymphocytes were readily generated and were effective for adoptive immunotherapy of metastasis induced by wild-type Ag104A sarcoma cells and may be useful for developing therapy for other poorly immunogenic tumors, including those in humans. Expand